A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

NCT02481674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: VX15/2503
DRUG: Placebo

Sponsor

Vaccinex Inc.

Collaborators

[object Object]